Poor
Needs Revision
Patient Risk:
Medium
Summary
Only a small subset of claims is supported by the provided label excerpts (notably thyroid C-cell tumor risk/contraindication). Many efficacy/mechanism/safety and comparative effectiveness claims are not supported by the supplied prescribing information text and therefore cannot be verified against the label.
Category Scores
Accurate Statements
Wegovy/semaglutide risk of thyroid C-cell tumors (including MTC) is discussed; monitoring is of uncertain value; WEGOVY is contraindicated in patients with personal/family history of MTC or MEN 2.
Supported by provided label excerpts: Section 5.1 (rodent thyroid C-cell tumors; unknown human relevance; uncertain value of routine calcitonin/ultrasound monitoring; counseling) and Section 4 (contraindications for personal/family history of MTC and MEN 2).
Unsupported Statements
Wegovy (semaglutide) is a medication approved by the FDA for chronic weight management in adults with obesity.
The provided label text does not include the indication section or any approval/indication wording.
Wegovy is a glucagon-like peptide-1 (GLP-1) receptor agonist.
The provided label excerpts focus on thyroid C-cell tumors and contraindications; no explicit statement in the supplied text confirms GLP-1 receptor agonist classification.
Wegovy works by mimicking the action of a natural hormone in the body that helps regulate appetite and glucose levels.
No mechanism-of-action/apetite/glucose-regulation statements are present in the supplied label text.
Wegovy slows down gastric emptying.
Not supported by the supplied label excerpts.
Wegovy reduces hunger.
Not supported by the supplied label excerpts.
Wegovy increases feelings of fullness.
Not supported by the supplied label excerpts.
Wegovy leads to a reduction in caloric intake and weight loss.
Not supported by the supplied label excerpts.
Wegovy improves insulin sensitivity.
Not supported by the supplied label excerpts.
Wegovy reduces the risk of developing type 2 diabetes.
Not supported by the supplied label excerpts.
In clinical trials, participants receiving Wegovy experienced a significant reduction in body weight compared with placebo.
No clinical trial efficacy results (placebo comparisons) are included in the provided label text.
Wegovy promotes sustainable weight loss.
Not supported by the supplied label excerpts.
Participants experienced a significant reduction in body weight over a period of 68 weeks while taking Wegovy.
No trial duration or 68-week outcome is included in the supplied label excerpts.
Wegovy improves insulin sensitivity and thereby reduces the risk of developing type 2 diabetes.
Not supported by the supplied label excerpts.
Wegovy reduces hunger and increases feelings of fullness.
Not supported by the supplied label excerpts.
Wegovy has been shown to improve mental health outcomes, including reduced symptoms of depression and anxiety.
Not supported by the supplied label excerpts.
Saxenda is less effective than Wegovy in promoting weight loss.
No comparative effectiveness information (Saxenda vs Wegovy) is included in the supplied label excerpts.
Participants receiving Wegovy experienced a greater reduction in body weight than those receiving Saxenda.
Not supported by the supplied label excerpts.
Orlistat is less effective than Wegovy in promoting weight loss.
No comparative effectiveness information (orlistat vs Wegovy) is included in the supplied label excerpts.
Participants receiving Wegovy experienced a greater reduction in body weight than those receiving Orlistat.
Not supported by the supplied label excerpts.
Common side effects of Wegovy include nausea, vomiting, diarrhea, and abdominal pain.
No general adverse reaction/side effect list is provided in the supplied label excerpts.
Common Wegovy side effects are typically mild and temporary.
Not supported by the supplied label excerpts.
Serious side effects of Wegovy include pancreatitis.
Pancreatitis is not mentioned in the supplied label excerpts.
Serious side effects of Wegovy include thyroid C-cell tumors.
Supported that thyroid C-cell tumors are described as a serious adverse reaction topic, but other serious adverse reactions (e.g., pancreatitis/AKI) are not supported; this statement is only partially verifiable from the provided text.
Serious side effects of Wegovy include increased risk of acute kidney injury.
Acute kidney injury is not mentioned in the supplied label excerpts.
Serious side effects of Wegovy are rare.
No incidence/frequency statements are included in the supplied label excerpts.
Serious side effects of Wegovy typically occur in individuals with pre-existing medical conditions.
No such generalization is included in the supplied label excerpts.
Wegovy may not be suitable for individuals with certain medical conditions including pancreatitis, thyroid C-cell tumors, and acute kidney injury.
Only thyroid C-cell tumor/MTC/MEN2 contraindication is supported by the provided excerpts; contraindications/eligibility for pancreatitis and acute kidney injury are not present in the supplied label text.
Contradictions
Important Omissions
Clear on-label contraindication phrasing for MTC/MEN2 and hypersensitivity risk (anaphylaxis/angioedema) if claiming broader suitability or contraindications.
Importance:
Moderate
For any statement about side effects (common/serious, severity, frequency, or who is at risk), the label would need to provide those details; they are absent from the supplied excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Several safety-related statements (e.g., pancreatitis, acute kidney injury risk; rarity; patient characteristics associated with serious adverse events) are not supported by the provided label excerpts. Unsupported safety claims could mislead risk assessment.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Needs Revision
Primary Issue
Most claims (indication/efficacy, mechanism, comparative effectiveness, and multiple adverse effect assertions) are not supported by the supplied FDA label excerpts.
Suggested Improvement
Limit assertions to information present in the provided label text, or supply the relevant label sections (Indications and Usage, Clinical Studies, Adverse Reactions, Warnings/Precautions, Contraindications) to accurately support each claim. Ensure contraindication wording is limited to MTC/MEN2 and prior serious hypersensitivity as shown in Section 4.